IL295490A - omecamtiv mecarbil tablet - Google Patents

omecamtiv mecarbil tablet

Info

Publication number
IL295490A
IL295490A IL295490A IL29549022A IL295490A IL 295490 A IL295490 A IL 295490A IL 295490 A IL295490 A IL 295490A IL 29549022 A IL29549022 A IL 29549022A IL 295490 A IL295490 A IL 295490A
Authority
IL
Israel
Prior art keywords
tablet formulation
omecamtiv mecarbil
film coating
tablet
core
Prior art date
Application number
IL295490A
Other languages
English (en)
Hebrew (he)
Inventor
Bi Mingda
Kiang Yuan-Hon
Lou Hao
Original Assignee
Amgen Inc
Bi Mingda
Yuan Hon Kiang
Lou Hao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Bi Mingda, Yuan Hon Kiang, Lou Hao filed Critical Amgen Inc
Publication of IL295490A publication Critical patent/IL295490A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
IL295490A 2020-02-10 2021-02-10 omecamtiv mecarbil tablet IL295490A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972506P 2020-02-10 2020-02-10
PCT/US2021/017429 WO2021163172A1 (en) 2020-02-10 2021-02-10 Omecamtiv mecarbil tablet

Publications (1)

Publication Number Publication Date
IL295490A true IL295490A (en) 2022-10-01

Family

ID=74858801

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295490A IL295490A (en) 2020-02-10 2021-02-10 omecamtiv mecarbil tablet

Country Status (9)

Country Link
US (1) US20230090391A1 (enExample)
EP (1) EP4103159A1 (enExample)
JP (1) JP7696353B2 (enExample)
CN (1) CN115279349A (enExample)
AU (1) AU2021221106A1 (enExample)
BR (1) BR112022015457A2 (enExample)
CA (1) CA3168513A1 (enExample)
IL (1) IL295490A (enExample)
WO (1) WO2021163172A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
MX2021009594A (es) 2017-06-30 2022-10-24 Amgen Inc Sintesis de omecamtiv mecarbil.
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
DK3594199T3 (da) 2018-07-09 2020-09-14 Fis Fabbrica Italiana Sintetici Spa Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808321A (en) * 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
JP6634368B2 (ja) 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法

Also Published As

Publication number Publication date
CA3168513A1 (en) 2021-08-19
WO2021163172A1 (en) 2021-08-19
BR112022015457A2 (pt) 2022-10-04
US20230090391A1 (en) 2023-03-23
JP7696353B2 (ja) 2025-06-20
JP2023513249A (ja) 2023-03-30
CN115279349A (zh) 2022-11-01
EP4103159A1 (en) 2022-12-21
AU2021221106A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US20230090391A1 (en) Omecamtiv mecarbil tablet
JP4463875B2 (ja) 医薬組成物
IL279035B2 (en) Pharmaceutical combination, composition and combination composition containing a glucokinase activator and a K-ATP channel blocker, method for their preparation and use
IL265777B2 (en) Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
JP2002524416A (ja) 持続放出型ラノラジン製剤
IL171870A (en) Modified-release tablet of bupropion hydrochloride
JP2017501201A (ja) Azd9291を含む医薬組成物
NZ574200A (en) Methods and medicaments for administration of ibuprofen and famotidine
IL297776A (en) Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
IL298525A (en) Pharmaceutical preparations of perletinib
JPWO2009060952A1 (ja) 新規製剤
NZ565591A (en) Trazodone and cross linked high amylose starch composition for once a day administration
IL280906B1 (en) Spice formulations containing 3-(5,3-dimethyl-h1-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid
EP4007568A1 (en) Pharmaceutical composition comprising dabigatran etexilate
US12161650B2 (en) Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
EP3796908B1 (en) Controlled release propiverine formulations
WO2022132066A1 (en) Homogenous compositions of propiverine hci formulations
CN118986905B (zh) 一种甲磺酸阿帕替尼片及其制备方法
EP4552633A1 (en) Pharmaceutical compositions comprising amorphous solid solutions of rivaroxaban and copovidone and preparation methods thereof
EP4601624A2 (en) Modified release tolcapone formulations
JP2025512011A (ja) デフェリプロンを含む修飾放出医薬製剤
US20120064161A1 (en) Modified release niacin pharmaceutical formulations